SCHEMBL5871398

SCHEMBL5871398

CC(C)C[Si](C)(C)OCCOc1ccc2c(c1)CCCC2C1CCN(CCc2ccc(F)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 9/20 0.42
DRD2 P14416 8/20 0.42
HTR1A P08908 7/20 0.42
HRH3 Q9Y5N1 5/20 0.42
ADRA1A P35348 6/20 0.42
ADRA1B P35368 5/20 0.42
ADRA1D P25100 2/20 0.42
HTR2C P28335 6/20 0.39
HRH1 P35367 5/20 0.39
HTR6 P50406 4/20 0.39
KCNH2 Q12809 3/20 0.39
DRD3 P35462 2/20 0.39
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38
HTR2B P41595 4/20 0.37
SIGMAR1 Q99720 1/20 0.37
SLC6A4 P31645 4/20 0.37
DRD1 P21728 3/20 0.37
DRD4 P21917 3/20 0.37
HRH2 P25021 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871394 0.88 ADRA1A (0.42) HTR2ADRD2HTR1AHRH3ADRA1A
SCHEMBL5871585 0.84 ADRA1A (0.48) HTR2ADRD2HTR1AHRH3ADRA1A
SCHEMBL5871443 0.82 HTR1A (0.53) HTR2ADRD2HTR1AHRH3ADRA1A
SCHEMBL5871114 0.75 HTR2A (0.46) HTR2ADRD2ADRA1AADRA1BADRA1D
SCHEMBL5871132 0.66 SIGMAR1 (0.61) HTR2ADRD2HTR2CHTR2BSIGMAR1
SCHEMBL5871090 0.62 SCD (0.45) HTR2ADRD2HTR1AADRA1AADRA1B
SCHEMBL5871488 0.62 SIGMAR1 (0.64) HTR2ADRD2HRH3HTR2CHTR2B
SCHEMBL5872075 0.62 HTR2A (0.53) HTR2ADRD2HTR1AHTR2CHTR6
SCHEMBL5872403 0.62 MTNR1B (0.56) DRD2HTR1AADRA1AADRA1BADRA1D
Hydrochloric Acid SCHEMBL5870972 0.61 MTNR1B (0.56) DRD2HTR1AADRA1AADRA1BADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071201-B2 Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline EISAI CO., LTD. (JP) 2006-07-04 US disclosed
US-6579881-B2 Indoles EISAI CO., LTD. (JP) 2003-06-17 US disclosed
US-6448243-B1 SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA EISAI CO., LTD. (JP) 2002-09-10 US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 US disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019531-A1 Indoles INMT, MUSK, MB HTR2A 209/4885DRD2 51/4885HTR1A 17/4885
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 HTR2A 143/4885DRD2 54/4885HTR1A 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.